Cipla all set to launch Favipiravir drug for treatment of COVID patients: CSIR
Posted by
www.biotecnika.org
An off-patent anti-viral drug, Favipiravir, originally discovered by
Fuji Pharma in Japan, has shown promise in clinical trials for
treatment of COVID-19 patients, especially in mild and moderate cases.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-all-set-to-launch-favipiravir-drug-for-treatment-of-covid-patients-csir/articleshow/77133469.cms
Subscribe to:
Post Comments (Atom)
Post a Comment